Therapeutic Fibrinolysis

Therapeutic fibrinolysis. What should follow?

B lood fluidity is a dynamic balance between thrombosis, its inhibition, and thrombolysis. In this vital balance, the process of clot formation and lysis produces new protein species. Activation peptides are formed when zymogens become active enzymes or when fibrinogen clots and enzyme inhibitor complexes develop as enzyme activity declines. Quantitative immunologic protein assays demonstrate n...

Fibrinolysis: Biochemistry, Clinical Aspects, and Therapeutic Potential.

The fibrinolytic system is responsible for physiological lysis of hemostatic plugs once vascular integrity has been restored after injury. The formation and regulation of plasmin proceeds in a very similar way to the formation and regulation of thrombin in the coagulation cascade.1 Complex regulatory pathways, which include cell surfaces, the fibrin surface, the structure of the fibrin clot, an...

A new diagnostic and therapeutic approach fibrinolysis and hemorrhage.

By J. C. HEUSON, W/. PEERS AND H. J. TAGNON I HE FOLLOWING STUDY gives evidence that the enzyme present in the plasma of a patient with acute fibrmnolysis was able to digest a protein substrate different from fibrinogen or fibrin. On tile other hand, this enzyme was found to l)e markedily inhibited in vitro by the soy bean trypsin inhibitor ( S.B.I. ) . On tile basis of this observation, an att...

Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.

Therapeutic fibrinolysis has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved little better than streptokinase in acute myocardial infarction. In contrast, endogenous fibrinolysis, using one-thousandth of the t-PA concentration, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 patency in 15% of patients with ac...

Comparative Fibrinolysis